CLCN7 Knockout HAP1 Cell Line

The choice depends on whether you are studying CLCN7 (chloride channel 7, CLC-7)'s role as a lysosomal Cl⁻/H⁺ antiporter or modeling osteopetrosis. The Knockout line is the standard tool for asking whether CLCN7 is required for these processes — CLCN7 is a member of the CLC family (CLC-1 to CLC-7 in humans) that functions as a 2 Cl⁻/1 H⁺ antiporter (rather than channel) localized to late endosomes and lysosomes; CLCN7 (with its β-subunit OSTM1) is required for lysosomal acidification and for the resorption lacuna acidification by osteoclasts. Overexpression is useful for studying CLCN7 in heterologous expression contexts. For lysosomal and bone biology research, the EDITGENE CLCN7 Knockout in HAP1 is highly informative — CLCN7 biallelic loss-of-function causes autosomal recessive infantile malignant osteopetrosis (ARO); dominant-negative CLCN7 mutations cause autosomal dominant Type II osteopetrosis (Albers-Schönberg disease); gain-of-function mutations cause lysosomal storage disease with hypopigmentation, organomegaly, and delayed motor development. Rescue with wild-type or transport-deficient CLCN7 (E245A, key glutamate for proton coupling) enables structure-function studies. The knockout is valuable for studying lysosomal biology, osteoclast biology, and osteopetrosis disease mechanisms.

Primary applications: • Lysosomal acidification: lysosomal pH analysis (LysoTracker, fluorescent probes) given CLCN7's role in lysosomal proton/chloride homeostasis. • OSTM1 partnership: OSTM1 β-subunit expression analysis given the obligate CLCN7-OSTM1 heterodimer. • Osteopetrosis modeling: rescue with patient-derived CLCN7 mutations (recessive ARO + dominant Albers-Schönberg) for genotype-function studies. • Lysosomal storage disease: rescue with gain-of-function CLCN7 mutations for lysosomal storage disease modeling. EDITGENE recommends this model for researchers investigating CLC family biology, lysosomal acidification, and osteopetrosis disease mechanisms.

Yes. CLCN7 rescue experiments require attention to lysosomal targeting and antiporter architecture: • Construct design: use a codon-modified CLCN7 sequence with a small intracellular tag (FLAG, HA). CLCN7 has the canonical CLC architecture (18 transmembrane domains, two CBS domains C-terminus) — preserve membrane topology. • Lysosomal localization validation: confirm lysosomal localization by LAMP1 co-localization. • OSTM1 partnership: CLCN7 requires OSTM1 for stability — rescue interpretation considers OSTM1 levels. • Transport-deficient rescue: E245A glutamate mutation abolishes proton coupling (uncoupled mode). • Osteopetrosis mutation rescue: patient-derived ARO and Albers-Schönberg CLCN7 mutations enable disease modeling. • Functional readout: rescue should restore lysosomal acidification measured by LysoTracker fluorescence. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.